Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Accounts Payables: 2022-2025

Historic Accounts Payables for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to $1.4 million.

  • Addex Therapeutics' Accounts Payables rose 34.16% to $1.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.4 million, marking a year-over-year increase of 34.16%. This contributed to the annual value of $903,436 for FY2024, which is 65.97% down from last year.
  • Addex Therapeutics' Accounts Payables amounted to $1.4 million in Q2 2025, which was up 30.91% from $1.1 million recorded in Q1 2025.
  • In the past 5 years, Addex Therapeutics' Accounts Payables ranged from a high of $4.2 million in Q2 2022 and a low of $907,267 during Q4 2024.
  • Over the past 3 years, Addex Therapeutics' median Accounts Payables value was $1.7 million (recorded in 2023), while the average stood at $2.0 million.
  • Examining YoY changes over the last 5 years, Addex Therapeutics' Accounts Payables showed a top increase of 34.16% in 2025 and a maximum decrease of 72.23% in 2025.
  • Over the past 4 years, Addex Therapeutics' Accounts Payables (Quarterly) stood at $3.1 million in 2022, then dropped by 13.57% to $2.7 million in 2023, then crashed by 66.25% to $907,267 in 2024, then skyrocketed by 34.16% to $1.4 million in 2025.
  • Its Accounts Payables was $1.4 million in Q2 2025, compared to $1.1 million in Q1 2025 and $907,267 in Q4 2024.